SHAREHOLDER ALERT: WeissLaw LLP Investigates Ortho Clinical Diagnostics Holdings plc

NEW YORK, Dec. 23, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Ortho Clinical Diagnostics Holdings plc ("Ortho" or the "Company") (NASDAQ: OCDX), in connection with the proposed acquisition of the Company by Quidel Corporation ("Quidel") (NASDAQ: QDEL). Under the terms of the merger agreement, the Company's shareholders will receive $7.14 in cash and 0.1055 shares of common stock in the combined company for each Ortho common share they own, representing implied per-share merger consideration of approximately $24.68 based upon Quidel's December 22, 2021 closing price of $166.24.  Upon completion of the transaction, Ortho shareholders are expected to own approximately 38% of the combined company. The transaction is valued at approximately $6.0 billion.

If you own Ortho shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/ocdx 
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
305 Broadway, 7^th Floor
New York, NY  10007
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw LLP is investigating whether (i) Ortho's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Ortho's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE WeissLaw LLP